Search clinical trials for: Omnitram

Total 32 results

Syntrix Biosystems, Inc.
National Institute on Drug Abuse (NIDA); DF/Net Research

Completed

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

Diabetic Neuropathies | Neuropathic Pain | Pain, Chronic

United States
Syntrix Biosystems, Inc.
National Institute on Drug Abuse (NIDA); Celerion

Completed

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

Pain

United States
Transplant Genomics, Inc.

Not yet recruiting

CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients (CLARITY)

Kidney Transplant Rejection
Stanford University
United Therapeutics

Completed

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Systemic Sclerosis | Calcinosis

United States
United Therapeutics

Withdrawn

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

United States
Syntrix Biosystems, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Omnitram Pharmacokinetic Study In Healthy Volunteers

Pain

United States
Syntrix Biosystems, Inc.
PRA Health Sciences; DF/Net Rearch; ITT Research Institute

Completed

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

Pain

United States
Brigham and Women's Hospital
United Therapeutics

Completed

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

Raynaud's Phenomenon

United States
United Therapeutics

Completed

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
United Therapeutics

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

PAH

United States
United Therapeutics
Lung Biotechnology PBC

Recruiting

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (ARTISAN)

Pulmonary Arterial Hypertension

United States
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
Hoffmann-La Roche

Completed

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Solid Tumor

Spain, United Kingdom
Hoffmann-La Roche

Completed

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Solid Tumor

United Kingdom, Netherlands
Gazi University

Completed

Comparison of Two Different Digital Methods in Occlusal Analysis

Occlusion | Dental Occlusion | Jaw Relationship | Centric Occlusion | Occlusal Analysis

Turkey
George Albert Fisher
Genentech, Inc.

Terminated

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Pamela L. Kunz
Genentech, Inc.

Terminated

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroblastoma | Multiple Endocrine Neoplasia | Pancreatic Neuroendocrine Tumors | Carcinoid Tumors | Adrenal Gland Tumors

United States
SCRI Development Innovations, LLC
Genentech, Inc.

Completed

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Neuroendocrine Carcinoma

United States
US Oncology Research
Genentech, Inc.

Terminated

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Breast Neoplasms | Malignant Tumor of the Breast

United States
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
University of Washington
United States Department of Defense

Recruiting

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Search clinical trials for: Omnitram

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations